SCHEMBL6286983

SCHEMBL6286983

COc1ccc(S(=O)(=O)n2cc(/C(C)=N\NC(=N)N)c3cc(Cl)ccc32)cc1OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 12/20 0.45
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 1/20 0.44
DRD2 P14416 1/20 0.44
SLC6A2 P23975 1/20 0.44
HTR2A P28223 1/20 0.44
HTR2C P28335 1/20 0.44
SLC6A4 P31645 1/20 0.44
HTR7 P34969 1/20 0.44
HRH1 P35367 1/20 0.44
ADRA1B P35368 1/20 0.44
SLC6A3 Q01959 1/20 0.44
KCNH2 Q12809 1/20 0.44
FLT1 P17948 1/20 0.42
FLT4 P35916 1/20 0.42
KDR P35968 1/20 0.42
ALDH1A1 P00352 2/20 0.39
TP53 P04637 1/20 0.39
PPARG P37231 1/20 0.39
PPARD Q03181 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6286990 1.00 HTR6 (0.45) HTR6CYP3A4CYP2D6DRD2SLC6A2
SCHEMBL6284982 0.90 HTR6 (0.44) HTR6CYP3A4CYP2D6DRD2SLC6A2
SCHEMBL6284975 0.90 HTR6 (0.44) HTR6CYP3A4CYP2D6DRD2SLC6A2
SCHEMBL6285571 0.88 HTR6 (0.55) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL6285576 0.88 HTR6 (0.55) HTR6PDE4APDE4BPDE4CPDE4D
SCHEMBL6280940 0.87 KCNH2 (0.47) HTR6CYP3A4CYP2D6DRD2SLC6A2
SCHEMBL6280938 0.87 KCNH2 (0.47) HTR6CYP3A4CYP2D6DRD2SLC6A2
SCHEMBL6285411 0.86 HTR6 (0.44) HTR6CYP3A4CYP2D6DRD2SLC6A2
SCHEMBL6285407 0.86 HTR6 (0.44) HTR6CYP3A4CYP2D6DRD2SLC6A2
SCHEMBL6285056 0.86 LMNA (0.46) HTR6CYP3A4CYP2D6ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US claimed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US claimed
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US disclosed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR2A HTR6 1/4885CYP3A4 1789/4885CYP2D6 333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.